We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+29.46%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$611M
AUM Growth
+$33.7M
Cap. Flow
-$56.3M
Cap. Flow %
-9.22%
Top 10 Hldgs %
48.78%
Holding
51
New
7
Increased
4
Reduced
2
Closed
11

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$18M
2
SLNO
Soleno Therapeutics
SLNO
+$7.41M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$6.74M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$6.34M
5
LQDA icon
Liquidia Corp
LQDA
+$4.34M

Top Sells

Rank Stock Value
1
GH icon
Guardant Health
GH
+$23M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$14.8M
3
MBX
MBX Biosciences
MBX
+$14.8M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$12.3M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.3B
$46.1M 7.54%
100,415
– –
CGEM icon
2
Cullinan Oncology
CGEM
$1.4B
$45.4M 7.42%
7,648,268
– –
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$33.1M 5.42%
760,022
– –
TRVI icon
4
Trevi Therapeutics
TRVI
$2.39B
$31.2M 5.1%
3,406,955
– –
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.64B
$27.9M 4.57%
1,720,741
– –
PTCT icon
6
PTC Therapeutics
PTCT
$5.85B
$26.9M 4.41%
438,477
– –
ZLAB icon
7
Zai Lab
ZLAB
$2.93B
$25.3M 4.13%
745,060
– –
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.74B
$21.2M 3.46%
+1,375,674
New +$18M
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.37B
$20.8M 3.4%
1,729,378
– –
TARS icon
10
Tarsus Pharmaceuticals
TARS
$3.15B
$20.3M 3.32%
341,496
– –
XENE icon
11
Xenon Pharmaceuticals
XENE
$5.81B
$20.2M 3.31%
503,398
+180,000
+56% +$6.34M
STOK icon
12
Stoke Therapeutics
STOK
$2.04B
$18.6M 3.04%
789,698
– –
DYN icon
13
Dyne Therapeutics
DYN
$4.68B
$18.3M 3%
1,446,361
– –
CMPX icon
14
Compass Therapeutics
CMPX
$432M
$17.8M 2.91%
5,075,970
-546,535
-10% -$1.73M
ALKS icon
15
Alkermes
ALKS
$7.95B
$16.5M 2.7%
549,262
– –
VERA icon
16
Vera Therapeutics
VERA
$2.46B
$16.4M 2.68%
563,075
– –
NTRA icon
17
Natera
NTRA
$47B
$15.9M 2.61%
98,924
– –
JANX icon
18
Janux Therapeutics
JANX
$1.1B
$15M 2.46%
614,282
– –
RVMD icon
19
Revolution Medicines
RVMD
$44.6B
$14.7M 2.41%
315,722
– –
CNTX icon
20
Context Therapeutics
CNTX
$35.3M
$14.2M 2.33%
14,705,882
– –
SRPT icon
21
Sarepta Therapeutics
SRPT
$2.2B
$13.5M 2.21%
700,000
+378,304
+118% +$6.74M
SPRY icon
22
ARS Pharmaceuticals
SPRY
$586M
$13.1M 2.14%
1,303,399
– –
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$424M
$12.7M 2.08%
3,903,381
+300
+0% +$945
RLAY icon
24
Relay Therapeutics
RLAY
$4.11B
$11.9M 1.95%
2,282,680
– –
RARE icon
25
Ultragenyx Pharmaceutical
RARE
$2.52B
$11.9M 1.95%
395,700
– –
1
2 3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2025 Portfolio in Review

As of Q3 2025, MPM BioImpact held 51 positions worth $611M, up 5.8% from $577M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

MPM BioImpact withdrew a net $56.3M in Q3 2025, closing 11 positions and reducing 2 holdings. Its most notable exit was Guardant Health, an estimated $23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, MPM BioImpact opened a new position in Syndax Pharmaceuticals worth $21.2M.

  • MPM BioImpact's largest Q3 2025 buy was Syndax Pharmaceuticals: 1,375,674 shares worth $21.2M.
  • MPM BioImpact added most to Soleno Therapeutics in Q3 2025, an estimated $7.41M increase.
  • MPM BioImpact's biggest Q3 2025 reduction was Cartesian Therapeutics, cutting an estimated $3.44M.
  • MPM BioImpact fully exited Guardant Health in Q3 2025, selling an estimated $23M.
  • MPM BioImpact's ten largest holdings make up 49% of its $611M portfolio in Q3 2025.
  • MPM BioImpact opened 7 new positions and closed 11 in Q3 2025.
  • MPM BioImpact's portfolio value rose 5.8% quarter-over-quarter to $611M.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.